{
    "root": "82e7bcd6-ebe3-4e29-85c5-f01c901ee0a1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Zembrace SymTouch",
    "value": "20250228",
    "ingredients": [
        {
            "name": "Sumatriptan Succinate",
            "code": "J8BDZ68989"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "ZEMBRACE SymTouch is indicated for the acute treatment of migraine with or without aura in adults.",
    "contraindications": "For subcutaneous use only. ( 2.1 ) Acute treatment of migraine: 3 mg Single dose. ( 2.1 ) Maximum dose in a 24-hour period: 12 mg. Separate doses by at least 1 hour. ( 2.1 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "ZEMBRACE SymTouch injection is contraindicated in patients with:\n                  \n                     Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions (5.1)].\n                     Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2)].\n                     History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions (5.4)]. \n                     Peripheral vascular disease [see Warnings and Precautions (5.5)].\n                     Ischemic bowel disease [see Warnings and Precautions (5.5)].\n                     Uncontrolled hypertension [see Warnings and Precautions (5.8)].\n                     Recent (i.e., within 24 hours) use of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT1) agonist [see Drug Interactions (7.1, 7.3)].\n                     Concurrent administration of an MAO-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)].\n                     Known hypersensitivity to sumatriptan (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)].\n                     Severe hepatic impairment [see Clinical Pharmacology (12.3)]."
}